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Abstract 
Population-scale drug prescription data linked with adverse drug reaction (ADR) data supports            
the fitting of models large enough to detect drug use and ADR patterns that are not detectable                 
using traditional methods on smaller datasets. However, detecting ADR patterns in large            
datasets requires tools for scalable data processing, machine learning for data analysis, and             
interactive visualization. To our knowledge no existing pharmacoepidemiology tool supports all           
three requirements. We have therefore created a tool for interactive exploration of patterns in              
prescription datasets with millions of samples. We use Spark to preprocess the data for machine               
learning and for analyses using SQL queries. We have implemented models in Keras and the               
scikit-learn framework. The model results are visualized and interpreted using live Python            
coding in Jupyter. We apply our tool to explore a 384 million prescription data set from the                 
Norwegian Prescription Database combined with a 62 million prescriptions for elders that were             
hospitalized. We preprocess the data in two minutes, train models in seconds, and plot the               
results in milliseconds. Our results show the power of combining computational power, short             
computation times, and ease of use for analysis of population scale pharmacoepidemiology            
datasets. The code is open source and available at:         
https://github.com/uit-hdl/norpd_prescription_analyses  
Introduction 
Pharmacoepidemiology is the study of the use of and the effects of drugs and other medical                
devices in large numbers of people [1]. An important effect studied in pharmacoepidemiologic             
studies is the risks of adverse effects such as hospital admissions coming from using drugs [2].                
Since there are many possible drug combinations such studies require very large cohorts to find               
any signals of adverse drug reactions (ADR), but also to adjust these findings with drug               
consumption rates. Our power calculations show that to study the difference in reporting rates              
for an ADR reported in 1 in 50000 drug users (normal reporting rate) between two drugs used                 
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by 10% and 2% of the population respectively, there is a need for data covering around 70                 
million people [3]. 
Consumption-adjusted ADR rates have only been estimated in smaller studies of relatively few             
individual drugs [4], [5]. We aim to provide such rates based on population-scale datasets with               
billions of prescriptions. We will use a retrospective cohort study design that combines             
prescription register data with spontaneous reports of drug combinations with suspected ADR.            
We aim to collect this data from several European countries covering a significant part of the                
population of Europe. Our aim is to use these largely unexploited datasets to explore how drugs                
are consumed by different populations in the data, and develop analyses of drug interactions              
and correlations. This is an exploratory, hypothesis-generating study. 
We observe three key requirements for exploring such large datasets. First, to enable             
interactive exploration the analysis time must be short, preferably less than 5 seconds. These              
big data computations therefore require large amounts of computing power, and thus the use of               
distributed computing, and hardware acceleration such as GPUs. Second, discovering patterns           
in the data requires developing and evaluating novel machine learning and statistical methods.             
It is therefore necessary to use machine learning frameworks. Third, the patterns must be              
interpreted. We therefore need interactive visualization tools. Summarized, we need an           
approach that provides intuitive ways to transform and interactively analyze the big datasets by              
abstracting away unnecessary details.  
To our knowledge, no existing pharmacoepidemiology tool satisfies all three requirements. Most            
studies use the classic epidemiological approach where they do statistical tests for a hypothesis              
about outcomes for specific exposures. We use an agnostic approach without any prior             
hypothesis, to find novel drug interactions and associated outcomes. We must therefore            
process a large dataset such that it can be explored with short response times. We use                
state-of-the-art big data processing and machine learning frameworks to implement novel data            
exploration methods. Big data processing frameworks such as Spark [6] are designed to utilize              
the aggregated computation power, RAM size, and I/O bandwidth of distributed computing to             
process low-dimensional data such as our ADR and prescription datasets. We can therefore             
utilize the computational power of distributed computers and GPUs to reduce the computation             
time for the analyses to a few seconds, and to scale to very large datasets. Machine learning                 
frameworks such as Keras (​https://keras.io/​) or Tensorflow [7] provide the computation power            
needed for deep learning methods, whereas scikit-learn [8] provides large libraries of machine             
learning and statistical methods. Finally, interactive scripting environments such as Jupyter           
Notebook (​https://jupyter.org/​) and RStudio (​https://rstudio.com/​) enable swift implementation of         
scripts and visualizations, which makes these excellent for data exploration and interpretation.  
We have developed a data transformation pipeline, data structures, machine learning methods            
and visualizations for exploring drug usage patterns and associated outcomes. These can be             
adapted for other analyses using an interactive programming environment that enables quick            
prototyping and iterative improvements. We have used our system to integrate and explore             
three datasets. Two are from the Norwegian Prescription Database: 370 million prescriptions            
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covering the entire Norwegian population and contains most prescriptions at pharmacies from            
2004-2014, and 60 million prescriptions with additional variables that cover Norwegian elders            
(>65 years). The third is a dataset with 1.9 million hospitalization records from the Norwegian               
Patient Registry.  
Design and implementation 
 
Figure 1: System architecture. 
The system architecture is centered around the Jupyter live code execution engine where the              
user writes code in a programming environment and interacts with the resulting visualizations             
(Figure 1). The engine connects all frameworks, tools and libraries. It enables the user to               
leverage multiple frameworks and libraries, and therefore implement and execute the entire            
workflow in a single environment. In addition to reducing the development time, analysis time              
can also be reduced since code changes do not require re-executing the entire analysis. 
We store the prescription data in the Spark big data framework. The user transforms,              
aggregates, and queries the data using SQL queries. The transformed data can be further              
cleaned and preprocessed using library functions executed in the live code execution engine.             
The user programs methods to train, tune, and validate machine learning models for the              
preprocessed data. These are executed in the Keras or scikit-learn machine learning            
frameworks. Finally, the user interprets the results using visualization and other libraries in the              
live execution engine. The results are stored as notebooks with all code and visualizations. 
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Data cleaning and transformation using Spark 
We use the Apache Spark [6] (​https://spark.apache.org/​) with Spark SQL’s DataFrame API for             
data cleaning and transformation. Spark has quickly become the industry standard for big data              
processing and it is offered by most cloud platforms, and it supports interactive queries on large                
datasets [6]. Our prescription dataset with hundreds of millions of rows and few columns is well                
suited for Spark. We therefore use Spark SQL to implement data transformation and             
aggregation. It has four main advantages. First, queries are only a few lines of code. For                
example, transformations can be expressed with group-by on one or multiple columns, and then              
applying an aggregate function to the grouped data. Second, the schemas can be used              
interactively. For example, we can check the state of the data between transformations by              
printing the schema or displaying a subset of the data. Third, we do not need to keep track of                   
the data type of each element with every transformation, nor the state of the data. Fourth, Spark                 
SQL provides a query optimizer.  
Drug use pattern recognition using scikit-learn 
We use scikit-learn (​https://scikit-learn.org/​) and Keras CIT (​https://keras.io/​) on Tensorflow [7]           
to implement, train, and evaluate our drug use pattern recognition algorithms. Sci-kit provides a              
large number of algorithms for preprocessing, and supervised and unsupervised learning. Keras            
is a high-level API for building and training deep learning models, which provides a simplified               
programming interface for designing deep learning models. Tensorflow supports GPU          
acceleration and distributed training.  
Explorative analyses using Jupyter 
We use Jupyter Notebook (​https://jupyter.org/​) for data exploration and interpretation. It           
supports many programming languages, including Python, Scala, Java, Go. Jupyter is           
increasingly used and supported by the data science community. The user interacts with a web               
app connected to a Jupyter web server that executes the code in a kernel. The user writes                 
blocks of code in cells, but the kernel maintains the notebook’s state between each cell. The                
results for an executed cell are displayed in an output cell below the code block. The cells also                  
support other formats, such as raw text or MarkDown         
(​https://daringfireball.net/projects/markdown/​), so notes and methodology descriptions can       
coexist with the code. The resulting code, visualizations, and documentation is the notebook             
can be saved as a file that can be executed to reproduce the analysis.  
We use the Spylon Jupyter kernel (​https://github.com/Valassis-Digital-Media/spylon-kernel​) to        
enable seamless transition between writing efficient preprocessing and computations in Scala,           
and interpretation in Python. It initializes a Spark Session on startup. The Spark Session              
connects to an existing Spark cluster if Spark is configured, otherwise it creates a virtual Spark                
cluster that runs on the same machine as the Jupyter environment. 
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We use the Spark DataFrame API, which provides support for SQL querying and registration of               
temporary tables. The Spark Session is shared between the interpreters, so the tables are also               
accessible from Python. We also extract and convert Spark Dataframe into Panda Dataframes             
(​https://pandas.pydata.org/​), so we can use these in Python for efficient queries on transformed             
and aggregated data (an example is in Figure 2). For visualization we use matplotlib              
(​https://matplotlib.org/​) and Plotly. We use the Python 3 kernel since Spylon has limited support              
for Plotly (​https://github.com/plotly/plotly.py​). 
# Get count of drugs that were prescribed to men who are alive 
men_a_dc ​=​ spark​.​sql​(​"select drugcode, count as count_a from 
men_a_drug_c"​).​sort​(​"drugcode"​).​where​(​"count>50"​).​toPandas​()#.​set_index​( 
"drugcode"​) 
 
# Get count of drugs that were prescribed to men that (later) died 
men_d_dc ​=​ spark​.​sql​(​"select drugcode, count as count_d from 
men_d_drug_c"​).​sort​(​"drugcode"​).​where​(​"count>23"​).​toPandas​()#.​set_index​( 
"drugcode"​) 
 
# Merge the two tables (living and dead), indexed by drug code 
# with two additional columns (drugcount of patients who are alive,  
# and of patients who are dead).  
# Drop rows (drugs) which are not prescribed in the live and dead population 
combined ​=​ men_a_dc​.​merge​(​men_d_dc​, 
on​=​"drugcode"​,​how​=​"inner"​).​sort_values​(​"drugcode"​).​fillna​(0.0).​reset_index​( 
drop​=​True​) 
Figure 2: Example from Supplementary Notebook 2. Spark-SQL is used to extract drug counts              
for dead and alive patients. The results are converted to Panda frames that are inner joined                
such that only the drugs present in both datasets are included. 
Case study: exploring drug use patterns and       
hospitalization 
An important goal in pharmacoepidemiology is finding and understanding adverse drug           
reactions (ADR) for combinations of drugs. For such studies the elderly population is especially              
interesting, since they have the highest drug consumption, and they are comedicated with many              
drugs at the same time. The elderly therefore have most ADR and the resulting health issues,                
unnecessary hospitalization, and death [9]. The challenge is detecting the cause for ADR for              
rarely prescribed comedication. In this case study, we demonstrate how large prescription data             
can be integrated and analyzed in a modern workflow. We explore drug consumption patterns              
that lead to hospitalization by finding drugs that are over-represented in elderly hospitalized             
patients. This is the first step towards finding ADRs for comedicated drugs, generating             
hypotheses for further analyses. 
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Drug usage datasets and variables 
Table 1: The three datasets used in this case study. 
Name Samples # drugs details 
General population 374.9M 856 Prescriptions in the period 2004-2014, NorPD. 
Representative of drug consumption in the 
general population. 
Elders 61.9M 1200 Prescriptions 2012-2014, NorPD. Patients > 
65 years of age. 
Patient registry 1.9M NA Hospitalization and diagnosis data for the 
people in the Elders data set. 
 
Drugs are encoded using The Anatomical Therapeutic Chemical Classification System          
(​https://www.whocc.no/atc_ddd_index/​). The ATC codes are organized in a hierarchy with five           
levels that describe for each drug the organ and disease the drug treats, as well as the                 
pharmacological target and chemical grouping in increasing details down to the specific            
chemical compound. Drugs that are chemically similar or used similarly share up to four levels in                
the ATC hierarchy. We use the ATC code hierarchy to adjust the dimensionality of the analyses.  
Disease and other health outcomes are coded with ICPC-2         
(​https://ehelse.no/kodeverk/icpc-2e--english-version​) and ICD-10 (​https://icd.who.int/en​) codes.     
The International Classification of Primary Care (ICPC-2) is commonly used by general            
practitioners in Norway. The International Statistical Classification of Diseases and Related           
Health Problems (ICD) is proposed by the World Health Organization as a global classification              
system. In Norway, ICD-10 is widely adopted in hospitals. 
Ingest and transform raw data to enable SQL queries 
To initialize the data structures we run data ingestion programs to convert the .csv data to more                 
suitable formats (Supplementary Notebook 1). First, we load the csv formatted data into Spark              
using Spark Session. This automatically parses the field names, and generates a schema for              
the data. We convert timestamps to unix-timestamp format and convert the birth year to integer               
format, then save the dataset back to disk in the Parquet format. Spark SQL automatically               
converts the data to a column format, builds various indexes, and partitions the data to multiple                
files. We cache these Spark SQL tables, which stores the data and results in RAM to reduce                 
query time.  
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Data exploration using SQL queries 
We start by comparing the drugs prescribed to patients that died during the 3 year period with                 
those that did not. We split the elders data into two subsets: patients that died between 2013                 
and 2017 (133.000) and those that were alive (640.000). In each group we count the number of                 
times each drug is prescribed and the total number of prescriptions (7.5 million for dead               
patients, 16.2 million for alive patients). We normalize the aggregated prescriptions by dividing             
each prescription count by the total number of prescriptions in each respective group. The              
resulting table contains the relative frequency of each drug per split. 
We compare the relative frequencies from the distribution of drug consumption of the two              
groups on the log scale. We choose the five drugs with the highest frequency, and then                
visualize the prescriptions of these drugs in dead patients as an aggregate in a 900 day time                 
frame prior to each patient's death. We aggregate consumption in 30-day windows by each              
patient's approximate days until death when the prescription occurs.  
The results (Figure 3) are as should be expected. Midazolam (N05CD08) is almost exclusively              
prescribed a very short period prior to death. It is a sedative, and is most likely used for                  
palliation. L01AX03, L02BB04, L01CA04 are all drugs used in cancer treatment, and we see              
that the prescriptions tend to occur more frequently when closer to patients death. Finally,              
dexamethasone (H02AB02) is used together with cancer treating drugs, specifically to treat or             
reduce the severity of adverse effects from the cancer medication, which tend to appear when               
the treatment is prolonged. 
Data preprocessing to binarize, clean and reduce data 
dimensionality 
To prepare the ​elders data for modeling we encode drug consumption as a binary variable, True                
or False. First, True for all ATC codes used in the period of interest. Second, True if the person                   
was hospitalized in the period. Otherwise, False. We then split the data by sex since some                
drugs are sex-specific. We remove patients with chronic disease, since they are often             
hospitalized because of their disease rather than drug usage. We consider as chronic those              
patients who had more than 10 hospitalizations between the years 2012 and 2014. 
For some analyses we adjust dimensionality using the hierarchical ATC codes. The lowest level              
(5) has >900 codes, while level 4 only has 160 codes. By using level 4 instead of 5 we lose                    
information about specific chemical compounds prescribed, but retain the chemical group to            
which the drug belongs and the function of its prescription. The resulting vectors are sparse,               
since on average only 4 of the level 4 codes are non-zero. 
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 Figure 3​: Norwegian drug prescription occurrence (30 day aggregates). The code for            
generating the figure is in Supplementary Notebook 3. 
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Differential drug use in hospitalized patients 
We apply a logistic regression model to investigate whether drugs are differentially used prior to               
hospitalization. Here we use 5-level ATC codes. We train the models using drug consumption              
estimated for 30 day windows for hospitalized and non-hospitalized patients.  
For hospitalized patients, we use the 30 day windows immediately before each hospitalization.             
To reduce the likelihood that our sampled dates are correlated strongly with any previous              
hospitalization, we only use windows where the period starts at least 60 days after the last                
hospitalization. For non-hospitalized patients, we randomly select 30 day windows in 2013. We             
consider a drug as used if it occurs somewhere in the 30-day window (Figure 4).  
 
Figure 4:​ Drug consumption estimation.  
We provide uncertainty intervals with the bootstrap [10], drawing 2000 bootstrap samples.            
Figure 5 shows estimated log odds ratios for hospitalization in terms of each active drug. I.e.,                
the odds associated with hospitalization for someone using the drug in the upper left corner is                
roughly ten times higher than that of someone not using the drug. Hence these estimates can                
be used for a list of likely suspects. Error bands are quite wide, suggesting that more data is                  
needed for accurate parameter estimates.  
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 Figure 5: All bootstrapped logistic regression parameters plus intervals denoting one standard            
error in each direction, based on 2000 bootstrap resamples. The figure is generated in              
Supplementary Notebook 4. 
Resource requirements and execution times 
We measured the resource requirements and execution times for training the model on a server               
with an Intel Xeon 4-core 2-way HT 3.8GHz processor, 64 GB RAM, an NVIDIA GTX 1080Ti                
with 11GB VRAM, and a 500GB SSD.  
Preprocessing a dataset takes about 2 minutes. Converting to Parquet reduces storage footprint             
for the datasets from 14.5 GB to 3.5 GB. These are therefore much faster to load from disk and                   
have increased read performance due to the indexing. 
The training time for logistic regression is 6.1 seconds. Most of our other exploratory statistical               
analyses have similar short execution times. However, bootstrap with 2000 iterations on a single              
core takes 15 hours and 12 minutes. All bootstrap resampling procedures can be run in parallel,                
so we can reduce execution time by using multiple cores. Doing a resampling procedure for               
error estimates may not be necessary here, but this does provide some suggestion as to what                
to expect doing something seriously compute intensive at this scale. 
Conclusions and future work 
We have designed a system which enables pharmacoepidemiological data exploration with           
interactive response times. It uses Apache Spark to enable analyses to scale to drug              
consumption and hospitalization data in 700 000 Norwegian elders, with 60 million prescriptions             
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and 1.9 million hospitalizations in a three-year period. We believe it will scale to data even larger                 
than the sources we have had available. 
We demonstrated the usefulness of the systems by exploring the association between drug             
usage patterns and hospitalizations among Norwegian elders. Using bootstrapping with linear           
regression, we found a prioritized list of drugs that are over- and underrepresented in the               
hospitalized group. This list can be used for further analyses, but a large number of drugs had                 
high variance so more data is necessary to decrease uncertainty in these estimates. 
The systems can be improved by replacing the spylon-kernel, which is not actively maintained,              
with Apache Toree (​https://toree.apache.org/​). We also believe the backend can be moved to a              
cloud service that provides managed Spark to take advantage of the continuous improvements             
and elasticity of cloud services. 
We believe that our system can be useful in pharmacoepidemiologic research in the future. The               
preprocessing can be further refined by improving data cleaning procedures. Furthermore, new            
features such as disease classifications can be added to enable machine learning models to              
learn more complex patterns between drug consumption and outcomes. Other outcomes such            
as any adverse drug reactions can be used and larger multi-national data can also be used for                 
such analyses. 
The code is open sourced under an MIT license and available at:            
https://github.com/uit-hdl/norpd_prescription_analyses  
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Supplementary materials 
Supplementary Notebook 1​:​ Ingest the general population prescription data set from NorPD.  
Supplementary Notebook 2​: Compare the distribution of drug consumption between live and            
dead patients by counting occurrence of drugs. The results is a Panda dataframe with drugs               
sorted by their estimated overrepresentation.  
Supplementary Notebook 3​: Plot the top 5 overrepresented drugs in dead patients using the              
dataframe from Supplementary Notebook 2.  
Supplementary Notebook 4​: ​Code and interactive visualizations for the bootstrapped logistic           
regression analysis for finding over- and under-represented drugs in hospitalization.  
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